 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for RAG2 |
 Gene summary |
| Basic gene information | Gene symbol | RAG2 |
| Gene name | recombination activating gene 2 | |
| Synonyms | RAG-2 | |
| Cytomap | UCSC genome browser: 11p13 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000536.3, NM_001243785.1,NM_001243786.1,NR_033666.1, | |
| Description | V(D)J recombination-activating protein 2 | |
| Modification date | 20141221 | |
| dbXrefs | MIM : 179616 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000175097 | ||
| HPRD : 08913 | ||
| Vega : OTTHUMG00000166393 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_RAG2 | |
| BioGPS: 5897 | ||
| Pathway | NCI Pathway Interaction Database: RAG2 | |
| KEGG: RAG2 | ||
| REACTOME: RAG2 | ||
| Pathway Commons: RAG2 | ||
| Context | iHOP: RAG2 | |
| ligand binding site mutation search in PubMed: RAG2 | ||
| UCL Cancer Institute: RAG2 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | HPA,TiGER | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | TestisThyroid glandThymus | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCTTHCATHYM | |
| Reference showing the relevant tissue of RAG2 | ||
| Description by TissGene annotations | Significant down-regulated DEG TissgsKTS CNV lost TissGeneKTS Fused withOncogene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for RAG2 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| KIRC | -0.516327638 | 1.412261251 | -1.928588889 | 2.02E-14 | 9.76E-14 |
| THCA | 1.080190889 | 6.154933262 | -5.074742373 | 8.48E-21 | 4.08E-19 |
| KICH | -0.600488027 | 1.977191973 | -2.57768 | 6.07E-08 | 2.90E-07 |
| KIRP | -0.498588402 | 1.039386598 | -1.537975 | 3.16E-06 | 1.44E-05 |
| Top |
| TissGene-miRNA for RAG2 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for RAG2 |
| TissGeneSNV for RAG2 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.E293K | SKCM | 2 |
| p.R159C | UCEC | 2 |
| p.G323E | SKCM | 2 |
| p.H207Y | SKCM | 2 |
| p.M502I | SKCM | 2 |
| p.R493K | SKCM | 1 |
| p.G95E | SKCM | 1 |
| p.G472E | LGG | 1 |
| p.C67F | THYM | 1 |
| p.K508N | HNSC | 1 |
| p.Q278* | LUAD | 1 |
| p.L348F | BLCA | 1 |
| p.R73H | HNSC | 1 |
| p.E480Q | LUSC | 1 |
| p.N364K | LUAD | 1 |
| p.P432R | SKCM | 1 |
| p.R137I | LUAD | 1 |
| p.R486I | LUAD | 1 |
| p.G221R | SKCM | 1 |
| p.M162I | STAD | 1 |
| p.D49H | LUSC | 1 |
| p.F399C | UCEC | 1 |
| p.G395V | LUAD | 1 |
| p.C350Y | UCEC | 1 |
| p.S160* | LUAD | 1 |
| p.R73C | BRCA | 1 |
| p.H455Y | SKCM | 1 |
| p.L461M | GBM | 1 |
| p.E412K | BLCA | 1 |
| p.S368L | STAD | 1 |
| p.F343L | COAD | 1 |
| p.L179M | STAD | 1 |
| p.N321S | SKCM | 1 |
| p.K150R | UCEC | 1 |
| p.E404* | SARC | 1 |
| p.P241T | LUAD | 1 |
| p.R123H | HNSC | 1 |
| p.P491S | SKCM | 1 |
| p.S447F | SKCM | 1 |
| p.K51N | SKCM | 1 |
| p.D424V | SKCM | 1 |
| p.K507I | SKCM | 1 |
| p.E412D | UCEC | 1 |
| p.H140N | READ | 1 |
| p.E404K | HNSC | 1 |
| p.V338F | LUAD | 1 |
| p.F271C | UCEC | 1 |
| p.A388E | UCEC | 1 |
| p.N295K | LUAD | 1 |
| p.L348F | CESC | 1 |
| p.V274F | GBM | 1 |
| p.L329R | STAD | 1 |
| p.L488P | SKCM | 1 |
| p.G511R | SKCM | 1 |
| p.Q90E | GBM | 1 |
| p.Q201* | SKCM | 1 |
| p.L197F | COAD | 1 |
| p.C420* | LIHC | 1 |
| p.W172* | SKCM | 1 |
| p.E87Q | BLCA | 1 |
| p.G149E | SKCM | 1 |
| p.G96W | LUSC | 1 |
| p.D334E | STAD | 1 |
| p.I289F | LUAD | 1 |
| p.T361I | BRCA | 1 |
| p.F345L | UCEC | 1 |
| p.R524W | LUAD | 1 |
| p.G255E | SKCM | 1 |
| p.L197I | UCEC | 1 |
| p.S314C | SKCM | 1 |
| p.A388G | LUSC | 1 |
| p.N281H | STAD | 1 |
| p.D374N | SKCM | 1 |
| p.I216F | LIHC | 1 |
| p.I112V | HNSC | 1 |
| p.T515P | HNSC | 1 |
| p.E412V | LIHC | 1 |
| p.E412G | STAD | 1 |
| p.A388V | UCEC | 1 |
| p.C420X | LIHC | 1 |
| p.T121N | UCEC | 1 |
| p.E298K | SKCM | 1 |
| p.L155I | UCEC | 1 |
| p.T436S | UCEC | 1 |
| p.G275S | KIRP | 1 |
| p.D460N | SKCM | 1 |
| Top |
| TissGeneCNV for RAG2 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for RAG2 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | BM152333 | RAG2-BACH2 | chr11:36619771 | chr6:90798680 |
| Top |
| TissGeneNet for RAG2 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (tumor) | RAG2, UBC, KPNA1, RAG1, SKP2, IPO5, DDB1, VPRBP (normal) |
 |  |
| Top |
| TissGeneProg for RAG2 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for RAG2 |
| TissGeneDrug for RAG2 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for RAG2 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0021051 | Immunologic Deficiency Syndromes | 32 | BeFree,GAD |
| umls:C0085110 | Severe Combined Immunodeficiency | 25 | BeFree,CLINVAR,GAD,LHGDN |
| umls:C1801959 | Histiocytic medullary reticulosis (disorder) | 13 | BeFree,CLINVAR |
| umls:C0009319 | Colitis | 10 | BeFree |
| umls:C0019693 | HIV Infections | 10 | BeFree |
| umls:C0023418 | leukemia | 8 | BeFree,LHGDN |
| umls:C0024299 | Lymphoma | 4 | BeFree |
| umls:C0023434 | Chronic Lymphocytic Leukemia | 3 | BeFree |
| umls:C0025202 | melanoma | 3 | BeFree |
| umls:C0027627 | Neoplasm Metastasis | 3 | BeFree |
| umls:C0002736 | Amyotrophic Lateral Sclerosis | 2 | BeFree |
| umls:C0009324 | Ulcerative Colitis | 2 | BeFree |
| umls:C0024141 | Lupus Erythematosus, Systemic | 2 | BeFree |
| umls:C0026764 | Multiple Myeloma | 2 | BeFree,GAD |
| umls:C0149678 | Epstein-Barr Virus Infections | 2 | BeFree |
| umls:C0153676 | Secondary malignant neoplasm of lung | 2 | BeFree |
| umls:C0678222 | Breast Carcinoma | 2 | BeFree |
| umls:C1292769 | Precursor B-cell lymphoblastic leukemia | 2 | BeFree |
| umls:C1961099 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | BeFree |
| umls:C0002312 | alpha-Thalassemia | 1 | BeFree |
| umls:C0003864 | Arthritis | 1 | BeFree |
| umls:C0003873 | Rheumatoid Arthritis | 1 | BeFree |
| umls:C0006142 | Malignant neoplasm of breast | 1 | BeFree |
| umls:C0006413 | Burkitt Lymphoma | 1 | BeFree |
| umls:C0007130 | Mucinous Adenocarcinoma | 1 | BeFree |
| umls:C0007131 | Non-Small Cell Lung Carcinoma | 1 | BeFree |
| umls:C0007134 | Renal Cell Carcinoma | 1 | BeFree |
| umls:C0014457 | Eosinophilia | 1 | BeFree |
| umls:C0018133 | Graft-vs-Host Disease | 1 | BeFree |
| umls:C0019270 | Hernia | 1 | BeFree |
| umls:C0019348 | Herpes Simplex Infections | 1 | BeFree |
| umls:C0020981 | Angioimmunoblastic Lymphadenopathy | 1 | BeFree |
| umls:C0021345 | Infectious Mononucleosis | 1 | BeFree,LHGDN |
| umls:C0023449 | Acute lymphocytic leukemia | 1 | BeFree |
| umls:C0023492 | Leukemia, T-Cell | 1 | BeFree |
| umls:C0024305 | Lymphoma, Non-Hodgkin | 1 | GAD |
| umls:C0024312 | Lymphopenia | 1 | GAD |
| umls:C0025362 | Mental Retardation | 1 | BeFree |
| umls:C0026850 | Muscular Dystrophy | 1 | BeFree |
| umls:C0026946 | Mycoses | 1 | BeFree |
| umls:C0027430 | Nasal Polyps | 1 | BeFree |
| umls:C0027960 | Nevus | 1 | BeFree |
| umls:C0027962 | Melanocytic nevus | 1 | BeFree |
| umls:C0028754 | Obesity | 1 | BeFree |
| umls:C0030305 | Pancreatitis | 1 | BeFree |
| umls:C0032584 | polyps | 1 | BeFree |
| umls:C0036920 | Sezary Syndrome | 1 | BeFree |
| umls:C0037199 | Sinusitis | 1 | BeFree |
| umls:C0162679 | Leukemic Infiltration | 1 | BeFree |
| umls:C0178468 | Autoimmune thyroid disease | 1 | BeFree |
| umls:C0178874 | Tumor Progression | 1 | BeFree |
| umls:C0206064 | Microvascular Angina | 1 | BeFree |
| umls:C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 1 | BeFree |
| umls:C0235974 | Pancreatic carcinoma | 1 | BeFree |
| umls:C0242723 | Parasitemia | 1 | BeFree |
| umls:C0267537 | Typhlitis | 1 | BeFree |
| umls:C0280100 | Solid tumour | 1 | BeFree |
| umls:C0333307 | Superficial ulcer | 1 | BeFree |
| umls:C0346647 | Malignant neoplasm of pancreas | 1 | BeFree |
| umls:C0376358 | Malignant neoplasm of prostate | 1 | BeFree |
| umls:C0400966 | Non-alcoholic Fatty Liver Disease | 1 | CTD_human |
| umls:C0553580 | Ewings sarcoma | 1 | BeFree |
| umls:C0598766 | Leukemogenesis | 1 | BeFree |
| umls:C0600139 | Prostate carcinoma | 1 | BeFree |
| umls:C0699790 | Colon Carcinoma | 1 | BeFree |
| umls:C0742597 | colon (non-specific) lesion | 1 | BeFree |
| umls:C0993582 | Arthritis, Experimental | 1 | CTD_human |
| umls:C1261473 | Sarcoma | 1 | BeFree |
| umls:C1262091 | Lymphocytic infiltration | 1 | BeFree |
| umls:C1264606 | Persistent infection | 1 | BeFree |
| umls:C1300682 | Acute and chronic colitis | 1 | BeFree |
| umls:C1306759 | Eosinophilic disorder | 1 | BeFree |
| umls:C1456781 | Benign melanocytic nevus | 1 | BeFree |
| umls:C1456873 | alpha^+^ Thalassemia | 1 | BeFree |
| umls:C1512326 | Human T-cell lymphotropic virus 1 infection | 1 | BeFree |
| umls:C1636667 | Disorder characterized by eosinophilia | 1 | BeFree |
| umls:C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | BeFree |
| umls:C2607914 | Allergic rhinitis (disorder) | 1 | BeFree |
| umls:C2673536 | Combined Cellular And Humoral Immune Defects With Granulomas | 1 | CLINVAR,CTD_human,ORPHANET,UNIPROT |
| umls:C2700553 | Omenn Syndrome | 1 | MGD,ORPHANET,UNIPROT |
| umls:C3665593 | Melanocytic nevus of skin | 1 | BeFree |
| umls:C1832322 | Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Negative, NK Cell-Positive | 0 | CTD_human,MGD,ORPHANET |
| umls:C2931884 | Reticuloendotheliosis, familial, with eosinophilia | 0 | CTD_human |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |